Fig. 4From: Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV studyParticipant self-reported fear of injection at baseline, week 12, and week 24 (mITT population). Based on patient response to the following question: “Please rate your current fear of self-injection.” mITT modified intent-to-treatBack to article page